HPV for cervical cancer screening (HPV FOCAL): Complete Round 1 results of a randomized trial comparing HPV-based primary screening to liquid-based cytology for cervical cancer

International Journal of Cancer

Volumn 140, Issue 2, 2017, Pages 440-448

  Ogilvie, Gina S ^a,b   Krajden, Mel ^a,b   van Niekerk, Dirk ^c,d   Smith, Laurie W ^d   Cook, Darrel ^b,d   Ceballos, Kathy ^d   Lee, Marette ^d   Gentile, Laura ^d   Gondara, Lovedeep ^d   Elwood Martin, Ruth ^a   Peacock, Stuart ^d   Stuart, Gavin ^a   Franco, Eduardo L ^e   Coldman, Andrew J ^d  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b BRITISH COLUMBIA CENTRE FOR DISEASE CONTROL   (Canada)

^c Lower Mainland Pathology and Laboratory Medicine   (Canada)

^d BRITISH COLUMBIA CANCER AGENCY   (Canada)

^e MCGILL UNIVERSITY   (Canada)

Author keywords

cervical cancer screening; HPV; human papillomavirus; molecular based testing

Indexed keywords

ADULT; AGED; ARTICLE; ATYPICAL SQUAMOUS CELL UNDETERMINED SIGNIFICANCE; CANCER DIAGNOSIS; CANCER SCREENING; COHORT ANALYSIS; COLPOSCOPY; CONTROLLED STUDY; DIAGNOSTIC TEST; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HUMAN; HUMAN PAPILLOMAVIRUS DNA TEST; LIQUID BASED CYTOLOGY; MAJOR CLINICAL STUDY; MIDDLE AGED; PAPANICOLAOU TEST; POPULATION RESEARCH; PREDICTIVE VALUE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SENSITIVITY AND SPECIFICITY; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CYTOLOGY; EARLY CANCER DIAGNOSIS; EMERGENCY HEALTH SERVICE; GENETICS; ISOLATION AND PURIFICATION; MASS SCREENING; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PATIENT REFERRAL; PROCEDURES; UTERINE CERVICAL NEOPLASMS; VAGINA SMEAR; VIROLOGY;

VIRUS DNA;

ADULT; AGED; COLPOSCOPY; DNA, VIRAL; EARLY DETECTION OF CANCER; FEMALE; HUMANS; MASS SCREENING; MIDDLE AGED; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; REFERRAL AND CONSULTATION; SENSITIVITY AND SPECIFICITY; TRIAGE; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS;

EID: 84995503371     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.30454     Document Type: Article

References (31)

1. International Agency for Research on Cancer (IARC).World Health Organization. Globocan 2012. Estimated cancer incidence mortality and prevalence worldwide 2012. Cervical cancer fact sheet. Retrieved 18 Jan, 2016 from: http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx
2. Vaccarella S, Lortet-Tieulent J, Plummer M, et al. Worldwide trends in cervical cancer incidence: impact of screening against changes in disease risk factors. Eur J Cancer 2013;49:3262–73.
3. Peto J, Gilham C, Fletcher O, et al. The cervical cancer epidemic that screening has prevented in the UK. Lancet 2004;364:249–56.
4. Munoz N, Bosch FX, de Sanjose S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003;348:518–27.
5. Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999;189:12–9.
6. Kash N, Lee M, Kollipara R, et al. Safety and efficacy data on vaccines and immunization to human papillomavirus. J Clin Med 2015;4:614–33.
7. Kirby T. FDA approves new upgraded Gardasil 9. Lancet Oncol 2015;16:e56. doi:10.1016/S1470-2045(14)71191-X
8. Schiller JT, Castellsagué X, Garland SM. A review of clinical trials of human papillomavirus prophylactic vaccines. Vaccine 2012;30:F123–F38. doi:10.1016/j.vaccine.2012.04.108.
9. Steenbergen RD, Snijders PJ, Heideman DA, et al. Clinical implications of (epi)genetic changes in HPV-induced cervical precancerous lesions. Nat Rev Cancer 2014;14:395–405. doi: 10.1038/nrc3728.
10. Bosch FX, Broker T, Forman D, et al. Comprehensive control of human papillomavirus infections and related diseases. Vaccine 2013;31: H1–H31.
11. El-Zein M, Richardson L, Franco EL. Cervical cancer screening of HPV vaccinated populations: cytology, molecular testing, both or none. J Clin Virol 2015;76: S62–S8. doi: 10.1016/j.jcv.2015.11.020
12. Wright TC, Stoler MH, Behrens CM, et al. Primary cervical cancer screening with human papillomavirus: end of study results from the ATHENA study using HPV as the first-line screening test. Gynecol Oncol 2015;136:189–97.
13. Ronco G, Dillner J, Elfstrom K, et al. Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomized controlled trials. Lancet 2014;383:524–32. doi:10.1016/S0140-6736(13)62218-7.
14. Kitchener HC, Almonte M, Thomson C, et al. HPV testing in combination with liquid-based cytology in primary cervical screening (ARTISTIC): a randomised controlled trial. Lancet Oncol 2009;10:672–82.
15. Bulkmans NW, Berkhof J, Rozendaal L, et al. Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial. Lancet 2007;370:1764–72.
16. Naucler P, Ryd W, Tornberg S, et al. Human papillomavirus and Papanicolaou tests to screen for cervical cancer. N Engl J Med 2007;357:1589–97.
17. Ronco G, Giorgi-Rossi P, Carozzi F, et al. Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial. Lancet Oncol 2010;11:249–57.
18. Kotaniemi-Talonen L, Anttila A, Malila N, et al. Screening with a primary human papillomavirus test does not increase detection of cervical cancer and intraepithelial neoplasia 3. Eur J Cancer 2008;44:565–71. doi: 10.1016/j.ejca.2007.12.002. Epub 2008 Jan 8.
19. Huh W, Ault KA, Chelmow D, et al. Use of primary high-risk human papillomavirus testing for cervical cancer screening: interim clinical guidance. Gynecol Oncol 2015;136:178–82. doi: 10.1016/j.ygyno.2014.12.022. Epub 2015 Jan 8.
20. Ogilvie GS, Krajden M, van Niekerk DJ, et al. Primary cervical cancer screening with HPV testing compared with liquid-based cytology: results of round 1 of a randomised controlled trial – the HPV FOCAL study. Br J Cancer 2012;107:1917–24. doi: 10.1038/bjc.2012.489. Epub 2012 Nov 20.
21. Ogilvie GS, van Niekerk DJ, Krajden M, et al. A randomized controlled trial of Human Papillomavirus (HPV) testing for cervical cancer screening: trial design and preliminary results (HPV FOCAL trial). BMC Cancer 2010;10:111. doi: 10.1186/1471-2407-10-111.
22. Smith L, Ogilvie G, Krajden M, et al. Methodological quality control measures of a population-based screening trial: HPV FOCAL. Presented at the 30th Annual International Papillomavirus Conference, Lisbon Portugal, September 17–21, 2015.
23. Schiffman M. Transitioning to a new era in cervical cancer screening. Gynecol Oncol 2015;136:175–7.
24. Saslow D, Solomon D, Lawson HW, et al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. Am J Clin Pathol 2012;137:516–42. doi: 10.1309/AJCPTGD94EVRSJCG
25. Forman D, Bray F, Brewster DH, Gombe Mbalawa C, Kohler B, Piñeros M, Steliarova-Foucher E, Swaminathan R, Ferlay J, eds (2013). Cancer incidence in five continents, Vol. X (electronic version). Lyon: International Agency for Research on Cancer. Available from: http://ci5.iarc.fr [Accessed January 29, 2016]
26. Dillner J, Rebolj M, Birembaut P, et al. Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study. Br Med J 2008;337:a1754. doi: 10.1136/bmja1754.
27. Castle P. Gynecologic cancer: new standard of care-HPV testing for cervical cancer screening. Nat Rev Clin Oncol 2015;12:194–6. doi: 10.1038/nrclinonc.2015.37. Epub 2015 Feb 24.
28. Rebolj M, Bonde J, Ejegod D, et al. A daunting challenge: human papillomavirus assays and cytology in primary cervical screening of women below age 30 years. Eur J Cancer 2015;51:1456–66. doi: 10.1016/j.ejca.2015.04.012. Epub 2015 May 12
29. Ogilvie GS, Cook DA, Taylor DL, et al. Population-based evaluation of type-specific HPV prevalence among women in British Columbia, Canada. Vaccine 2013;31:1129–33. doi: 10.1016/j.vaccine.2012.09.085. Epub 2012 Dec 25.
30. Castle PE, Schiffman M, Herrero R, et al. A prospective study of age trends in cervical human papillomavirus acquisition and persistence in Guanacaste, Costa Rica. J Infect Dis 2005;191:1808–16. Epub 2005 May 2.
31. Gustinucci D, Giorgi Rossi P, Cesarini E, et al. Use of cytology, E6/E7 mRNA, and p16INK4a-Ki-67 to define the management of human papillomavirus (HPV)-positive women in cervical cancer screening. Am J Clin Pathol 2016;145:35–45. doi: 10.1093/ajcp/aqv019.